钙离子拮抗剂类降压药在肾脏病中的合理应用

Rational application of antihypertensive calcium channel blockers in renal diseases

中国人群高血压发病率较高,其中继发性高血压第一位的病因就是慢性肾脏病(CKD)。对于CKD高血压患者首选血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体拮抗剂(ARB)类药物,而单药治疗往往血压控制不佳,需联合其它降压药物治疗。钙离子拮抗剂(CCB)是一线降压药物,既往考虑其对肾脏副作用而较少应用于CKD患者。随着研究进展及新型制剂的研发,CCB类药物在CKD高血压治疗中亦有一定地位及优势,合理的应用可改善肾脏病预后,给患者带来益处。

The incidence of hypertension is high in the Chinese population. And the first cause of secondary hypertension is chronic kidney disease （CKD）. To control the hypertension in CKD patients, angiotensin converting enzyme inhibitor （ACEI） or angiotensin receptor blocker （ARB） is the first choice. However, as single drug use of ACEI or ARB does not have satisfactory effect in controlling the hypertension of CKD patients, combination of other antihypertensive drugs is usually needed. Calcium channel blockers （CCB） are first-line antihypertensive drugs, but were less used in CKD patients previously due to their adverse effects. With the research progress and the development of new preparations, CCB have their certain places and advantages in treatment of hypertension patients with CKD. Rational application of CCB can improve prognosis of the kidney so as to benefit the patients.